Sight Sciences, Inc. (SGHT)
NASDAQ: SGHT · Real-Time Price · USD
3.280
-0.050 (-1.50%)
At close: Aug 1, 2025, 4:00 PM
3.270
-0.010 (-0.30%)
After-hours: Aug 1, 2025, 4:10 PM EDT

Company Description

Sight Sciences, Inc., an ophthalmic medical device company, focuses on the development and commercialization of surgical and nonsurgical technologies for the treatment of eye prevalent diseases.

The company operates in two segments, Surgical Glaucoma and Dry Eye. Its products include OMNI surgical system, an implant-free, handheld, single-use, therapeutic technology that enables ophthalmic surgeons to perform a comprehensive procedure indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma, as well as for the catheterization and transluminal viscodilation of Schlemm’s canal and cutting of the trabecular meshwork to reduce intraocular pressure in adult patients with open-angle glaucoma; and SION surgical instrument, a bladeless manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

The company also provides TearCare system, a dry eye device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality.

It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States.

The company was incorporated in 2010 and is headquartered in Menlo Park, California.

Sight Sciences, Inc.
Sight Sciences logo
CountryUnited States
Founded2011
IPO DateJul 15, 2021
IndustryMedical Devices
SectorHealthcare
Employees216
CEOPaul Badawi

Contact Details

Address:
4040 Campbell Avenue, Suite 100
Menlo Park, California 94025
United States
Phone877 266 1144
Websitesightsciences.com

Stock Details

Ticker SymbolSGHT
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$24.00
CIK Code0001531177
CUSIP Number82657M105
ISIN NumberUS82657M1053
Employer ID80-0625749
SIC Code3841

Key Executives

NamePosition
Paul BadawiCo-Founder, President, Chief Executive Officer and Director
Dr. David Badawi M.D.Co-Founder, Chief Technology Officer and Director
Alison Perry BauerleinChief Financial Officer, Principal Financial and Accounting Officer and Treasurer
Jeremy B. Hayden J.D.Chief Legal Officer and Corporate Secretary
Brenton TaylorExecutive Vice President of Operations
Steve R. Tamayo Jr.Vice President and Chief Ethics and Compliance Officer
Dr. Reay H. Brown M.D.Chief Medical Officer
Matthew W. LinkChief Commercial Officer
Dr. Manohar K. Raheja Ph.D.Executive Vice President of Research and Development
Jim RodbergVice President of Finance and Corporate Controller

Latest SEC Filings

DateTypeTitle
Jul 3, 2025144Filing
Jul 3, 2025144Filing
Jul 2, 2025144Filing
Jul 2, 2025144Filing
Jul 1, 2025144Filing
Jun 5, 20258-KCurrent Report
May 30, 2025SDForm - SD
May 19, 2025144Filing
May 15, 2025SCHEDULE 13G/AFiling
May 8, 202510-QQuarterly Report